NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Harmony Biosciences Holdings, Inc. (HRMY) Stock Analysis

Harmony Biosciences Holdings, Inc. (HRMY) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

HRMY

$42.25

+$0.39 (+0.93%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HRMY with… →

HRMY Key Statistics

As of Sep 4, 2026
Trading
Open
$41.50
Previous Close
$41.86
Day's Range
41.36–42.34
52-Week Range
25.52–43.49
Volume
661.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.93
Valuation
Market Cap
$2.46B
P/E Ratio
13.67
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
6.32
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.56
EPS (ttm)Profit attributable to each share over the last twelve months.
3.09
Financials (FY)
Revenue (FY)
$868.45M+21.51%
Net Income (FY)
$158.69M+9.07%
Profit marginThe share of revenue left as profit after all costs and taxes.
18.88%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
58.24M
1-Year Return
+16.39%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
819.11K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

HRMY Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+12.91%
2025+8.75%
2024+6.53%
2023−41.38%
2022+29.22%
2021+17.95%
2020 (partial year)−2.32%

As of September 4, 2026.

HRMY Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$868.45M$158.69M18.3%
2024$714.73M$145.49M20.4%
2023$582.02M$128.85M22.1%
2022$437.86M$181.47M41.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$868.45M$670.11M$208.47M$158.69M18.3%
2024$714.73M$557.92M$190.83M$145.49M20.4%
2023$582.02M$460.79M$192.03M$128.85M22.1%
2022$437.86M$354.37M$120.19M$181.47M41.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

HRMY Valuation vs Biotechnology Median

Median of 656 stocks
MetricHRMYBiotechnology medianvs median
P/E13.6712.579% above
P/S ratio2.5615.260.2x the median
Profit margin18.88%0.00%18.9 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Harmony Biosciences Holdings, Inc. (HRMY) carries a market capitalisation of $2.46B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 293 employees.

HRMY last closed at $42.25 on September 4, 2026. That is +$0.39 (+0.93%) against the previous close. Over the past 52 weeks the price has ranged from $25.52 to $43.49. The latest close sits 65.56% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $868.45M. That is +21.51% against the prior fiscal year, when revenue was $714.73M. The same year closed with net income of $158.69M. That is +9.07% against the prior fiscal year. Profit margin runs at 18.88%. That is 18.9 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 3.09.

Across the 4 fiscal years on file, revenue moves from $437.86M in 2022 to $868.45M in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 13.67 times earnings. That is 8.75% above the Biotechnology median of 12.57. On forward earnings the ratio is 6.32. Measured against sales, the shares trade at 2.56 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.93. Daily returns over the trailing 6 years annualize to a volatility of 51.71%. Over the trailing twelve months the price has returned +16.39%. Across 5 years the annualized return works out at +3.17%.

Growth & Income

No dividend is on file for HRMY.

Across the complete calendar years on file, 2022 returned +29.22% and 2023 returned −41.38%. Of the 5 complete calendar years on file, 4 finished higher. 2026 is still running; the price is +12.91% year to date.

Peer Comparison

Harmony Biosciences Holdings, Inc. (HRMY) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Harmony Biosciences Holdings, Inc. HRMY $2.46B 13.7
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Harmony Biosciences Holdings, Inc. trades at a P/E of 13.7.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Visit website →